Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
Study Results
Related Studies
Escitalopram for the Prevention of PEGASYS-associated Depression in Hepatitis C Virus-infected Patients (CIPPAD)
This study has been completed.
Study NCT00136318 Information provided by Charite University, Berlin, Germany
First Received on August 26, 2005. Last Updated on March 20, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Depression
Additional conditions recognized in this trial
Depressive Disorder
Hepatitis
Hepatitis A
Hepatitis C
Hepatitis C, Chronic
More general conditions related to this trial
Behavioral Symptoms
Digestive System Diseases
Enterovirus Infections
Flaviviridae Infections
Hepatitis, Chronic
Hepatitis, Viral, Human
Liver Diseases
Mental Disorders
Mood Disorders
Picornaviridae Infections
RNA Virus Infections
Virus Diseases
Interventions listed in this trial
Escitalopram
Placebo
Peginterferon alfa-2a
Ribavirin
Additional drug interventions recognized in this trial
Citalopram
Dexetimide
Interferon-alpha
Interferons
More general drug interventions related to this trial
Anti-Dyskinesia Agents
Anti-Infective Agents
Antidepressive Agents
Antidepressive Agents, Second-Generation
Antimetabolites
Antineoplastic Agents
Antiparkinson Agents
Antiviral Agents
Autonomic Agents
Central Nervous System Agents
Cholinergic Agents
Cholinergic Antagonists
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Muscarinic Antagonists
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Parasympatholytics
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Agents
Serotonin Uptake Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Charite University, Berlin, Germany
Back to top of Main Content
